Explore this article's sources with AI
Follow PeptideMethods on Google
China semaglutide equivalence trial
A 481-person Chinese trial found equivalent 32-week HbA1c lowering for two study semaglutide injections in people using metformin.
Why we wrote this. A new comparative trial needs a plain-language reading that keeps its short-term equivalence result separate from product switching and personal treatment decisions.
In this article (5 sections)
A Chinese phase 3 trial compared an injection described by the authors as domestic semaglutide with original semaglutide in adults whose type 2 diabetes was inadequately controlled with metformin. At week 32, the reported average HbA1c change was minus 1.80 percentage points in the domestic-product group and minus 1.85 percentage points in the original-product group. The study met its prespecified equivalence criterion for the primary outcome[1]. That is useful comparative evidence. It is not a reason to change, start or source a medicine without a clinician who can assess the person, product and local label.
What this trial tested
The report describes a multicentre, randomised, positive-controlled phase 3 equivalence trial at 39 research centres in China. Recruitment ran from 13 March 2024 to 9 April 2025. Investigators assigned 481 participants in a one-to-one ratio to domestic semaglutide injection or original semaglutide injection while their diabetes remained inadequately controlled with metformin[1]. Randomisation was stratified by baseline HbA1c below 8.5% or at least 8.5%.
The primary endpoint was change in HbA1c from baseline at week 32. HbA1c is a laboratory measure that reflects average blood glucose over the preceding months. The protocol set an equivalence margin of plus or minus 0.4 percentage points. This design asks whether the two trial treatments produced sufficiently similar glucose-lowering results within that predefined range. It does not ask whether either product is best for every person with type 2 diabetes.
For context on the medicine class, see our semaglutide evidence overview. A comparison trial is narrower than a full treatment decision. A prescriber still has to consider the diagnosis, other medicines, medical history, contraindications and the locally authorised product.
The 32-week glucose result
Both analysis sets contained 481 participants: 241 in the domestic-semaglutide group and 240 in the original-semaglutide group. The least-squares mean HbA1c change at week 32 was minus 1.80% in the domestic group and minus 1.85% in the original-product group. The between-group difference was 0.05 percentage points, with a 95% confidence interval from minus 0.13 to 0.23 percentage points[1]. Because that interval sat inside the protocol's equivalence margin, the authors concluded that the primary endpoint supported equivalence over the study period.
The same paper reports an equivalent result at week 20. It also reports no statistically significant difference between groups in the proportions reaching HbA1c below 7.0% or at or below 6.5% at weeks 20 and 32[1]. Those figures should not be read as a personal target. HbA1c goals can differ according to age, hypoglycaemia risk, complications and other clinical factors.
An equivalence result is also not proof that two products are identical in every respect. It addresses a stated endpoint in a defined population over a defined duration. Manufacturing controls, approved indications, device instructions, supply pathways and post-marketing surveillance sit outside the numerical HbA1c comparison reported in this abstract.
What the safety figures can and cannot say
Overall adverse events occurred in 205 of 241 participants in the domestic group, or 85.06%, and 200 of 240 participants in the original-product group, or 83.33%. Drug-related hypoglycaemic events occurred in one participant and six participants, respectively. The authors report no statistically significant differences for these comparisons[1]. A non-significant difference in a trial of this size is not proof that the risks are identical or absent.
The current US Ozempic label lists semaglutide injection as a prescription treatment with specific indications, contraindications, warnings and adverse-reaction information. It includes warnings on pancreatitis, diabetic retinopathy complications and hypoglycaemia when used with insulin secretagogues or insulin[2]. That US label does not determine the status or instructions for a product studied in China. It does illustrate why a headline safety percentage cannot replace product-specific prescribing information.
Readers can review the safety context on our semaglutide safety page. Anyone with severe or persistent symptoms, or a concern about a possible adverse effect, should seek timely medical advice rather than trying to interpret a trial table alone.
What remains unknown
The follow-up reported here lasted 32 weeks. That is long enough to answer the trial's short-term HbA1c question, but it cannot settle rare harms, longer-term durability, cardiovascular outcomes or product performance after routine use. The article abstract also does not establish interchangeability across jurisdictions or an individual switching plan.
The wording domestic semaglutide is the paper's description of the experimental injection. It should not be converted into a broad claim about all locally manufactured semaglutide products. Product names, regulatory approvals and dispensing routes need confirmation from the regulator and the authorised local product information. Our US semaglutide regulation guide covers a separate jurisdiction and is not a substitute for Chinese regulatory advice.
A careful takeaway
This 481-person Chinese equivalence trial found similar short-term HbA1c lowering and broadly similar reported overall adverse-event rates for the two study injections in people already using metformin. That supports the study's defined comparison. It does not establish that every semaglutide injection is interchangeable, that a reader should alter treatment, or that the result applies outside the trial population. Discussing a medicine change with the clinician who manages the diabetes care remains the safer next step.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What did the Chinese semaglutide trial compare?
It randomised 481 adults with type 2 diabetes inadequately controlled with metformin to a domestic semaglutide injection or original semaglutide injection. The primary outcome was change in HbA1c at week 32.
Did the two injections have the same HbA1c result?
The trial met its prespecified equivalence criterion. The reported week-32 average HbA1c changes were minus 1.80% and minus 1.85%, with a between-group difference of 0.05 percentage points.
Does this mean every semaglutide injection is interchangeable?
No. The trial addresses a defined comparison in one population over 32 weeks. It does not establish interchangeability across every product, device, country or individual treatment plan.
Did the study prove the two products have identical safety?
No. Overall adverse-event rates were similar in this trial, but a short comparative study cannot exclude every difference, rare harm or longer-term outcome. Local authorised product information and clinical advice still matter.
Sources
- [1]Efficacy and safety of domestic semaglutide injection in people with type 2 diabetes inadequately controlled with metformin: multicentre randomised phase 3 equivalence trial. Zhonghua Yi Xue Za Zhi (2026). PMID 42933873Tier 1 · primary↩
- [2]DailyMed. Ozempic (semaglutide) injection, current US prescribing informationTier 1 · primary↩
No revisions yet. First published .